Are you Dr. Fu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 41 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Unit 0455
Houston, TX 77030Phone+1 713-792-4318Fax+1 713-745-3855- Is this information wrong?
Summary
- Dr. Siqing Fu, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Mississippi, and Washington. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of RochesterFellowship, Hematology and Medical Oncology, 2001 - 2004- University of RochesterResidency, Internal Medicine, 1999 - 2001
Yale-New Haven Medical CenterInternship, Internal Medicine, 1998 - 1999
Tongji Medical UniversityClass of 1985
Certifications & Licensure
CA State Medical License 2008 - Present
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
WA State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
MS State Medical License 2023 - 2024
OK State Medical License 2020 - 2024- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Hepatic Arterial Infusion (HAI) of Abraxane Start of enrollment: 2008 Jun 01
- Trientine and Carboplatin in Advanced Malignancies Start of enrollment: 2010 Jul 01
- Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...Subbiah, V., Coleman, N., Piha-Paul, S., Tsimberidou, A., Janku, F., Rodon, J., Pant, S., Dumbrava, E., Fu, S., Hong, D., Zhang, S., Sun, M., Jiang, Y., Roszik, J., So...> ;Cancer Research Communications. 2024 Feb 12
- Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.Coleman, N., Stephen, B., Ahnert, J., Wright, J., Fessahaye, S., Ouyang, F., Yilmaz, B., Fu, S., Karp, D., Subbiah, V., Piha-Paul, S., Meric-Bernstam, F., Naing, A.> ;Cancer Medicine. 2024 Feb 1
- Therapeutic Role of Synthetic Lethality in-Deficient Malignancies.Kyaw Z Hein, Bettzy Stephen, Siqing Fu> ;Journal of Immunotherapy and Precision Oncology. 2024 Feb 1
- Join now to see all
Press Mentions
MD Anderson Research Highlights for December 19, 2022December 19th, 2022- Soricimed Appoints Leading North American Cancer Researcher Dr. Siqing Fu to Its Scientific Advisory BoardDecember 13th, 2022
- Greenfire Bio to Update Progress on Phase 1 Clinical Trial for SIK2/SIK3 Inhibitor, GRN-300, in Ovarian Cancer at the ASCO Annual Meeting 2022May 31st, 2022
- Join now to see all
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
